The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: How different are they from their normal counterparts?

Sędek, Łukasz; Bulsa, Joanna; Sonsala, Alicja; Twardoch, Magdalena; Wieczorek, M.; Malinowska, Iwona; Derwich, Katarzyna; Niedźwiecki, Maciej; Sobol‐Milejska, Grażyna; Kowalczyk, Jerzy; Mazur, Bogdan; Szczepanski, T

doi:10.1002/cytob.21176

Cited by 37 publications

(28 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…After antigen labeling and cytometer detection, events with high side scatter (SSC) and low forward scatter (FSC) were excluded as signal interference on the FSC/SSC dot plot. Then the CD45dimCD19+ cells were gated and immunophenotyped to identify hematogones according to previous reports 45,46 , which was CD10+, CD34− or +, CD38+, CD20 + (partially), HLA-DR+, CD13− and CD33−.…”

Section: Methodsmentioning

confidence: 99%

The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease

Liao

Zheng

Jin

et al. 2019

Sci Rep

View full text Add to dashboard Cite

This study was aimed to dissect the prognostic significances of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell acute lymphoblastic leukemia(ALL) without minimal residual disease(MRD) after the induction chemotherapy cycle. A total of 113 ALL patients who have received standardized chemotherapy cycle were analyzed. Cases that were not remission after induction chemotherapy or have received stem cell transplantation were excluded. Flow cytometry was used to quantify the levels of hematogones and CD34+ myeloblasts in bone marrow aspirations, and the patients were grouped according to the levels of these two precursor cell types. The long-term relapse-free survival(RFS) and recovery of peripheral blood cells of each group after induction chemotherapy were compared. The results indicated that, after induction chemotherapy, patients with hematogones ≥0.1% have a significantly longer remission period than patients with hematogones <0.1% (p = 0.001). Meanwhile, the level of hematogones was positively associated with the recovery of both hemoglobin and platelet in peripheral blood, while CD34+ myeloblasts level is irrelevant to the recovery of Hb and PLT in peripheral blood, level of hematogones and long-term prognosis. This study confirmed hematogones level after induction chemotherapy can be used as a prognostic factor for ALL without MRD. It is more applicable for evaluation prognosis than CD34+ myeloblasts.

show abstract

Section: Methodsmentioning

confidence: 99%

The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease

Liao

Zheng

Jin

et al. 2019

Sci Rep

View full text Add to dashboard Cite

show abstract

“…The most commonly employed markers for LB overlap with those of HG. 8 In addition to phenotypic similarities, LB and their nonneoplastic counterparts share similar morphological features, making their morphologic distinction in bone marrow difficult. 9 Increasing levels of HG have been described in different situations, particularly in the phase of bone marrow regeneration, following chemotherapy or bone marrow transplantation 10,11 or in healthy infants.…”

mentioning

confidence: 99%

Easy discrimination of hematogones from lymphoblasts in B‐cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio

Nagant¹,

Casula²,

Janssens³

et al. 2018

Int J Lab Hematology

View full text Add to dashboard Cite

show abstract

“…Given that the immunophenotype of leukaemic cells resembles that of BCPs, it is particularly difficult to detect residual leukaemic cells during therapy intervals, i.e. when regenerating BCPs are abundantly present (Dworzak et al, 2002;Mirkowska et al, 2013;Sedek et al, 2014). Leukaemic cells can be discriminated from regenerating BCPs by the expression of BCP-ALL specific markers, by overexpression or underexpression of Bcell differentiation markers or by asynchronous expression of B-cell differentiation markers (Hurwitz et al, 1988;Campana & Coustan-Smith, 1999;Lucio et al, 1999;van Lochem et al, 2004;Szczepanski et al, 2006;Seegmiller et al, 2009;Gaipa et al, 2013).…”

mentioning

confidence: 99%

Detailed immunophenotyping of B‐cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection

et al. 2017

View full text Add to dashboard Cite

Flow cytometric detection of minimal residual disease (MRD) in children with B-cell precursor acute lymphoblastic leukaemia (BCP-ALL) requires immunophenotypic discrimination between residual leukaemic cells and B-cell precursors (BCPs) which regenerate during therapy intervals. In this study, EuroFlow-based 8-colour flow cytometry and innovative analysis tools were used to first characterize the immunophenotypic maturation of normal BCPs in bone marrow (BM) from healthy children, resulting in a continuous multiparametric pathway including transition stages. This pathway was subsequently used as a reference to characterize the immunophenotypic maturation of regenerating BCPs in BM from children treated for BCP-ALL. We identified pre-B-I cells that expressed low or dim CD34 levels, in contrast to the classical CD34 pre-B-I cell immunophenotype. These CD34 pre-B-I cells were relatively abundant in regenerating BM (11-85% within pre-B-I subset), while hardly present in healthy control BM (9-13% within pre-B-I subset; P = 0·0037). Furthermore, we showed that some of the BCP-ALL diagnosis immunophenotypes (23%) overlapped with CD34 pre-B-I cells. Our results indicate that newly identified CD34 pre-B-I cells can be mistaken for residual BCP-ALL cells, potentially resulting in false-positive MRD outcomes. Therefore, regenerating BM, in which CD34 pre-B-I cells are relatively abundant, should be used as reference frame in flow cytometric MRD measurements.

show abstract

The immunophenotypes of blast cells in B-cell precursor acute lymphoblastic leukemia: How different are they from their normal counterparts?

Cited by 37 publications

References 0 publications

The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease

The prognostic significance of hematogones and CD34+ myeloblasts in bone marrow for adult B-cell lymphoblastic leukemia without minimal residual disease

Easy discrimination of hematogones from lymphoblasts in B‐cell progenitor acute lymphoblastic leukemia patients using CD81/CD58 expression ratio

Detailed immunophenotyping of B‐cell precursors in regenerating bone marrow of acute lymphoblastic leukaemia patients: implications for minimal residual disease detection

Contact Info

Product

Resources

About